Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine in Soft Tissue Sarcoma Resection
NCT03867188Phase 1Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bupivacaine in soft tissue sarcoma (STS) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of participants with peak pain scores measured by VAS less than 7 at 24 hours. Started Jan 2019; status: terminated.
02
Drugs
bupivacaine
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03867188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867188.